Patients have long received cancer treatments at the maximum tolerated dose on a regular schedule. Could a more sophisticated approach save lives? Elie Dolgin meets one mathematical biologist whose theories are now being tested in the clinic to see if they can improve the efficacy of today's anticancer arsenal.
This is a preview of subscription content, log in via an institution to check access.
References
Chmielecki, J. et al. Sci. Transl. Med. 3, 90ra59 (2011).
Foo, J., Chmielecki, J., Pao, W. & Michor, F. J. Thorac. Oncol. 7, 1583–1593 (2012).
Norton, L. & Simon, R. Cancer Treat. Rep. 61, 1307–1317 (1977).
Citron, M.L. et al. J. Clin. Oncol. 21, 1431–1439 (2003).
Goldie, J.H. & Coldman, A.J. Cancer Treat. Rep. 63, 1727–1733 (1979).
Bonadonna, G., Zambetti, M., Moliterni, A., Gianni, L. & Valagussa, P. J. Clin. Oncol. 22, 1614–1620 (2004).
Gatenby, R.A., Silva, A.S., Gillies, R.J. & Frieden, B.R. Cancer Res. 69, 4894–4903 (2009).
Silva, A.S. et al. Cancer Res. 72, 6362–6370 (2012).
Foo, J., Drummond, M.W., Clarkson, B., Holyoake, T. & Michor, F. PLoS Comput. Biol. 5, e1000503 (2009).
Leder, K. et al. Cell 156, 603–616 (2014).
Verhaak, R.G. et al. Cancer Cell 17, 98–110 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. The mathematician versus the malignancy. Nat Med 20, 460–463 (2014). https://doi.org/10.1038/nm0514-460
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0514-460
- Springer Nature America, Inc.